Millendo Therapeutics Inc (NASDAQ:MLND) Receives Average Rating of “Buy” from Brokerages

Shares of Millendo Therapeutics Inc (NASDAQ:MLND) have earned an average rating of “Buy” from the nine research firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $25.29.

Several equities research analysts have recently commented on MLND shares. Zacks Investment Research raised shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Tuesday. Wedbush started coverage on shares of Millendo Therapeutics in a research report on Thursday. They issued an “outperform” rating and a $24.00 target price for the company. Oppenheimer started coverage on shares of Neurocrine Biosciences in a research report on Tuesday. They issued an “outperform” rating and a $100.00 target price for the company. ValuEngine cut shares of Welbilt from a “hold” rating to a “sell” rating in a research report on Wednesday, June 12th. Finally, CIBC dropped their target price on shares of Stuart Olson from C$5.00 to C$4.00 in a research report on Tuesday.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC purchased a new position in Millendo Therapeutics during the 4th quarter valued at about $113,000. Private Advisors LLC lifted its position in Millendo Therapeutics by 9.1% during the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock valued at $229,000 after acquiring an additional 1,279 shares during the period. Tibra Equities Europe Ltd purchased a new position in Millendo Therapeutics during the 1st quarter valued at about $303,000. BlackRock Inc. purchased a new position in Millendo Therapeutics during the 4th quarter valued at about $203,000. Finally, Worth Venture Partners LLC purchased a new position in Millendo Therapeutics during the 4th quarter valued at about $206,000. 44.07% of the stock is owned by institutional investors.

Shares of NASDAQ:MLND traded down $0.14 on Monday, hitting $10.51. The company had a trading volume of 30,144 shares, compared to its average volume of 102,244. The stock’s 50-day moving average is $12.56. Millendo Therapeutics has a 1 year low of $6.77 and a 1 year high of $17.34. The company has a quick ratio of 7.83, a current ratio of 7.83 and a debt-to-equity ratio of 0.02. The company has a market cap of $142.56 million, a price-to-earnings ratio of -0.60 and a beta of 2.61.

Millendo Therapeutics (NASDAQ:MLND) last posted its earnings results on Wednesday, May 15th. The company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.08). As a group, research analysts forecast that Millendo Therapeutics will post -3.27 EPS for the current fiscal year.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Read More: How the Consumer Price Index (CPI) is calculated?

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.